

Darren R Feldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8341688/publications.pdf>

Version: 2024-02-01

169
papers

10,508
citations

50170

46
h-index

37111

96
g-index

172
all docs

172
docs citations

172
times ranked

14932
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
2	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	0.8	584
3	High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 3466-3473.	0.8	369
4	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	2.9	324
5	Medical Treatment of Advanced Testicular Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 672.	3.8	307
6	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018, 4, 29.	18.1	299
7	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.	0.8	298
8	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	1.3	280
9	Testicular Cancer Survivorship: Research Strategies and Recommendations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1114-1130.	3.0	260
10	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
11	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2712-2720.	0.8	197
12	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	0.8	192
13	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1529-1554.	2.3	174
14	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4007.	0.8	147
15	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
16	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	2.0	109
17	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	0.8	108
18	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1505-1512.	0.8	95

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-Induced Peripheral Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju044-dju044.	3.0	94
20	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
21	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
22	Presence of Somatic Mutations within <i>PIK3CA</i> , <i>AKT</i> , <i>RAS</i> , and <i>FGFR3</i> but not <i>BRAF</i> in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720.	3.2	88
23	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1211-1222.	0.8	86
24	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
25	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	0.8	83
26	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	1.2	79
27	Natural immunity to pluripotency antigen OCT4 in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8718-8723.	3.3	78
28	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. <i>PLoS ONE</i> , 2012, 7, e51563.	1.1	78
29	Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities. <i>Oncologist</i> , 2011, 16, 543-553.	1.9	74
30	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€“Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	0.8	72
31	Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. <i>Annals of Oncology</i> , 2014, 25, 663-668.	0.6	71
32	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	0.8	70
33	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
34	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€“An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 345-351.	0.8	69
35	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	1.2	66
36	Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , 2017, 23, 3325-3333.	3.2	65

#	ARTICLE	IF	CITATIONS
37	Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. <i>International Journal of Developmental Biology</i> , 2013, 57, 273-280.	0.3	64
38	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3018-3028.	0.8	63
39	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5757-5768.	3.2	63
40	Late Cardiovascular Toxicity Following Chemotherapy for Germ Cell Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 537-544.	2.3	56
41	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	0.8	56
42	Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. <i>Journal of Cancer</i> , 2011, 2, 374-377.	1.2	55
43	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , 2012, 30, 1773-1781.	1.2	50
44	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	2.0	50
45	The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. <i>European Journal of Cancer</i> , 2012, 48, 340-346.	1.3	49
46	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.2	49
47	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302.	0.9	46
48	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
49	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411.	3.2	44
50	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
51	Fertility preservation strategies for male patients with cancer. <i>Nature Reviews Urology</i> , 2013, 10, 463-472.	1.9	42
52	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.	1.2	41
53	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
54	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40

#	ARTICLE	IF	CITATIONS
55	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
56	Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. <i>European Urology</i> , 2016, 70, 1082-1083.	0.9	38
57	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
58	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	0.6	34
59	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. <i>Oncologist</i> , 2018, 23, 316-323.	1.9	34
60	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083.	2.0	33
61	Interrogation of a Context-Specific Transcription Factor Network Identifies Novel Regulators of Pluripotency. <i>Stem Cells</i> , 2015, 33, 367-377.	1.4	32
62	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	0.9	32
63	Late Relapse of Testicular Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 359-368.	0.8	31
64	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
65	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
66	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	2.0	30
67	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
68	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
69	Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.	0.5	28
70	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769.	0.9	28
71	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	3.9	28
72	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	3.2	27

#	ARTICLE	IF	CITATIONS
73	Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 974-975.	3.0	26
74	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
75	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	2.0	25
76	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
77	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.	0.8	25
78	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 257-265.	2.3	24
79	Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 26.e9-26.e15.	0.8	23
80	Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. <i>Journal of Urology</i> , 2016, 195, 33-40.	0.2	23
81	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	1.9	22
82	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
83	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
84	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	1.2	21
85	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. <i>American Journal of Human Genetics</i> , 2012, 91, 379-383.	2.6	21
86	Phase II Trial of Pegylated Interferon- β 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	0.9	20
87	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.2	20
88	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
89	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846.	1.1	18
90	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	0.8	17

#	ARTICLE	IF	CITATIONS
91	A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2011, 25, 557-576.	0.9	16
92	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Review of Anticancer Therapy, 2011, 11, 1093-1105.	1.1	16
93	Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. Urology, 2012, 79, 361-364.	0.5	16
94	Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. Advances in Urology, 2018, 2018, 1-7.	0.6	16
95	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 5913-5924.	3.2	16
96	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	2.6	16
97	Treatment Options for Stage I Nonseminoma. Journal of Clinical Oncology, 2014, 32, 3797-3800.	0.8	15
98	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in "Time to Start Backing Out. Journal of Clinical Oncology, 2018, 36, 837-840.	0.8	15
99	Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways. Cancers, 2021, 13, 787.	1.7	15
100	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. Urology, 2011, 77, 368-372.	0.5	14
101	State-of-the-Art Management of Germ Cell Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 319-323.	1.8	14
102	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports in Oncology, 2021, 14, 430-438.	0.3	14
103	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine, 2022, 11, 2801-2816.	1.3	14
104	Update in germ cell tumours. Current Opinion in Oncology, 2015, 27, 177-184.	1.1	13
105	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019, 74, 171-183.	1.6	13
106	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). Cancer, 2020, 126, 5311-5318.	2.0	13
107	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 459-468.	2.3	13
108	Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear and Hearing, 2022, 43, 794-807.	1.0	13

#	ARTICLE	IF	CITATIONS
109	Salvage high-dose chemotherapy for germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 355-362.	0.8	12
110	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	0.5	12
111	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	0.5	12
112	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24â€‰%900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa017.	1.4	12
113	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
114	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa022.	1.4	11
115	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
116	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	0.6	11
117	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470.	1.2	10
118	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumorsâ€”An Update. <i>Urology</i> , 2011, 77, 655-659.	0.5	10
119	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.2	10
120	Hearing Loss in Adult Survivors of Childhood Cancer Treated with Radiotherapy. <i>Children</i> , 2018, 5, 59.	0.6	10
121	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	1.5	9
122	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107.	2.1	9
123	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020, 26, 6550-6558.	3.2	9
124	Beyond Stage I Germ Cell Tumors: Current Status Regarding Treatment and Long-Term Toxicities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e180-e190.	1.8	9
125	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
126	Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006, 20, 1745-53; discussion 1756.	0.4	9

#	ARTICLE	IF	CITATIONS
127	The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study. <i>Cancer</i> , 2020, 126, 1776-1783.	2.0	8
128	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
129	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , 2008, 1, 22.	6.9	7
130	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
131	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.	0.5	7
132	Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. <i>European Urology</i> , 2019, 76, 612-614.	0.9	7
133	Comprehensive Genomic Analysis of Metastatic Non-“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7
134	A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. <i>Investigational New Drugs</i> , 2022, 40, 1087-1094.	1.2	7
135	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6
136	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131.	0.5	6
137	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.	0.5	6
138	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 336-336.	0.8	6
139	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.	0.5	5
140	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	0.9	5
141	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020, 144, 111-116.	0.5	5
142	Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. <i>Investigational New Drugs</i> , 2021, 39, 1656-1663.	1.2	5
143	The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. <i>Oncology</i> , 2010, 24, 761-3.	0.4	5
144	The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach. <i>Oncology</i> , 2016, 30, 653-64.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287.	0.8	4
146	The conundrum of clinical trials in adult germ-cell tumours. <i>Lancet Oncology</i> , The, 2013, 14, 14-15.	5.1	4
147	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 523-528.	1.4	4
148	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1129-1138.	1.1	4
149	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1141-1149.	0.7	4
150	Paclitaxel, Ifosfamide and Cisplatin (TIP) Beyond Its Original Indication for Salvage Treatment of Germ Cell Tumors. <i>Oncology Research and Treatment</i> , 2011, 34, 410-411.	0.8	3
151	The role of high-dose chemotherapy in the management of germ cell tumors. <i>Current Opinion in Oncology</i> , 2014, 26, 284-293.	1.1	3
152	Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors. <i>Blood</i> , 2018, 132, 87-87.	0.6	3
153	Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4510-4510.	0.8	3
154	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
155	Editorial Comment. <i>Urology</i> , 2014, 84, 890-891.	0.5	2
156	Reply to L.C. Pagliaro et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2327-2328.	0.8	2
157	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
158	Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4543-4543.	0.8	2
159	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	2
160	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. <i>Nature Reviews Urology</i> , 2008, 5, 78-79.	1.4	1
161	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e740-e740.	0.8	1
162	Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4534-4534.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.. Journal of Clinical Oncology, 2016, 34, 1537-1537.	0.8	1
164	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nature Clinical Practice Oncology, 2007, 4, 508-509.	4.3	0
165	Microwave Ablation (MWA) for the Treatment of a Solitary, Chemorefractory Testicular Cancer Liver Metastasis. CardioVascular and Interventional Radiology, 2015, 38, 488-493.	0.9	0
166	Are Some Cases of Somatic Type Malignancy Potentially Avoidable?. Journal of Urology, 2016, 196, 11-13.	0.2	0
167	Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome. Case Reports in Nephrology and Dialysis, 2017, 7, 49-54.	0.3	0
168	Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2020, 38, 3074-3075.	0.8	0
169	Epidemiology, Biology, and Genetics of Adult Male Germ Cell Tumors. , 2015, , 431-450.		0